- The probability of death will double in the next 10 years if middle-aged and elderly people can’t stand on one foot for 10 seconds
- Maradona death: Medical team members will be tried for alleged murder
- Tuberculosis infection in Singapore: About 30% of the 574 people in the same community positive
- Swollen axillary lymph nodes associated with the COVID-19 vaccine last longer than initially reported
- How to relieve the fatigue symptoms of patients with Parkinson’s disease?
- Frontiers in Oncology: Mushroom extract can clear HPV infection
UK MHRA accepts marketing application for almetinib
- How long can the patient live after heart stent surgery?
- More than 500 new drugs for blood diseases are in development
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
UK MHRA accepts marketing application for almetinib.
On June 14, EQRx, Inc announced that the UK Medicines and Health Products Regulatory Agency (MHRA) has accepted a Marketing Authorization Application (MAA) for the third-generation EGFR tyrosine kinase inhibitor (TKI) almetinib for the treatment of adults First-line treatment of locally advanced or metastatic non-small cell lung cancer.
The application is primarily based on data from the pivotal Phase III AENEAS trial, which is the first time EQRx has submitted a marketing application to a regulatory agency.
AENEAS (NCT03849768) is a randomized, double-blind, multicenter Phase III study to evaluate the efficacy and safety of almetinib versus gefitinib as first-line treatment for adults with locally advanced or metastatic EGFR-mutant non-small cell lung cancer sex.
Conducted by Hansoh Pharmaceuticals, the study enrolled 429 patients who were randomized to receive almetinib (n=214) or gefitinib (n=215). The study met its primary endpoint, data have been published in the Journal of Clinical Oncology, and data on almetinib activity in CNS metastases were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
(source:internet, reference only)